Seminars in oncology最新文献

{"title":"From tissue architecture to clinical insights: Spatial transcriptomics in solid tumor studies","authors":"Arpit Sharma ,&nbsp;Shruti S. Raut ,&nbsp;Alok Shukla ,&nbsp;Shivani Gupta ,&nbsp;Abha Mishra ,&nbsp;Amit Singh","doi":"10.1016/j.seminoncol.2025.152389","DOIUrl":"10.1016/j.seminoncol.2025.152389","url":null,"abstract":"<div><div>Cancer is a highly heterogeneous disease, and its diagnosis, prognosis, and therapeutic responsiveness depend not only on genetic alterations but also on the intricate organization of cells within the tumor microenvironment (TME). Spatial transcriptomics—a suite of techniques that preserves the spatial context of gene expression in intact tissue—has revolutionized our ability to decipher tumor architecture and intercellular communication. This review provides an in‐depth analysis of recent advancements in spatial transcriptomics technologies and their applications in solid tumor research. We first describe the evolution of spatial transcriptomics from early in situ hybridization methods to state‐of‐the‐art imaging‐ and sequencing‐based platforms. Next, we discuss how spatially resolved transcriptomics is transforming cancer research by revealing the molecular landscapes of tumor cores, invasive edges, and immunological niches. The integration of spatial transcriptomics with single‐cell multiomics and advanced computational algorithms is leading to the identification of novel prognostic and predictive biomarkers. Despite tremendous progress, challenges remain in terms of technical resolution, data processing, sample preparation, and clinical standardization. Finally, we highlight emerging trends—including three-dimensional (3D) spatial profiling, multimodal integration, and the use of artificial intelligence and Deep learning—to envision a future in which spatial transcriptomics will serve as a pivotal tool for precision oncology. Together, these developments promise to refine cancer biomarker studies and ultimately improve patient outcomes.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152389"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baicalein and baicalin in cancer therapy: Multifaceted mechanisms, preclinical evidence, and translational challenges","authors":"Xavier Capó ,&nbsp;Rajesh Kumar ,&nbsp;Abhay Prakash Mishra ,&nbsp;Manisha Nigam ,&nbsp;Neti Waranuch ,&nbsp;Miquel Martorell ,&nbsp;Farukh Sharopov ,&nbsp;Daniela Calina ,&nbsp;Dragoș Popa ,&nbsp;William N. Setzer ,&nbsp;Javad Sharifi-Rad ,&nbsp;Raffaele Pezzani","doi":"10.1016/j.seminoncol.2025.152377","DOIUrl":"10.1016/j.seminoncol.2025.152377","url":null,"abstract":"<div><div>Natural compounds with multitargeted actions are gaining prominence in oncology for their potential to complement and transcend the limitations of conventional therapies. Among them, baicalein and baicalin, two flavonoids primarily isolated from <em>Scutellaria baicalensis</em>, have attracted attention for their broad-spectrum anticancer properties. This review synthesizes current evidence from cellular systems, animal models, and early-phase clinical studies, exploring their pharmacological potential and translational relevance. Both molecules interfere with key hallmarks of cancer, including proliferation, survival, angiogenesis, metastasis, and immune evasion. Mechanistically, they modulate interconnected signaling cascades governing apoptosis, inflammation, and cell cycle control, and they enhance tumor sensitivity to chemotherapy and radiotherapy. <em>In-vivo</em> models consistently demonstrate tumor growth inhibition, while clinical data suggest a favorable safety profile, even at relatively high oral doses. However, their clinical translation remains hampered by limited solubility, poor oral bioavailability, and rapid metabolism, factors that continue to constrain their therapeutic window. Efforts to overcome these barriers through structural modification, encapsulation strategies, and advanced delivery systems are underway, yet few have advanced beyond preclinical validation. Despite these pharmacokinetic limitations, baicalein and baicalin remain compelling candidates for integrative oncological approaches. Their pleiotropic mechanisms, combined with low toxicity and synergistic behavior with standard therapies, position them as prototypes for a new generation of phytochemical-based anticancer agents. Continued work is needed to resolve formulation challenges and define precise molecular targets, but their trajectory reflects the growing scientific and clinical momentum around rationally designed natural compound therapeutics.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152377"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactylation in radiosensitivity regulation: Mechanistic insights and recent advances","authors":"Caiqiang Zhu ,&nbsp;Meng Tian ,&nbsp;Xiaoke Di ,&nbsp;Jin Liu ,&nbsp;Huanhuan Chen ,&nbsp;Lu Xu ,&nbsp;Ying Liu ,&nbsp;Xinchen Sun ,&nbsp;Zhaoyue Zhang","doi":"10.1016/j.seminoncol.2025.152394","DOIUrl":"10.1016/j.seminoncol.2025.152394","url":null,"abstract":"<div><div>Lactylation, as a novel post-translational modification, has gained a lot of attention in the biomedical field in recent years. Lactylation is not only related to cellular metabolism but also increasingly prominent in the tumor microenvironment, particularly in regulating radiation sensitivity. This review aims to explore the potential connection between lactylation modification and the regulation of radiation sensitivity. Current research shows that lactylation might be crucial in how tumor cells respond to radiotherapy by influencing energy metabolism, gene expression, and cell signaling. However, despite preliminary studies revealing the association between lactylation and radiation sensitivity, the understanding of its specific mechanisms remains insufficient, necessitating more systematic research to elucidate this process. Therefore, by analyzing the biological basis of lactylation modification, its role in tumor metabolism, and its relationship with radiotherapy, we summarize the importance and application prospects of lactylation in tumor treatment, providing direction for future research.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152394"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes","authors":"Xing Zhong ,&nbsp;Xinyu Zhu ,&nbsp;Xiaoxia Ma ,&nbsp;Lili Zhou ,&nbsp;Xiu Luo ,&nbsp;Ping Li ,&nbsp;Yi Ding ,&nbsp;Jianfei Fu ,&nbsp;Jiaqi Bo ,&nbsp;Muye Yang ,&nbsp;Aibin Liang ,&nbsp;Yu Zeng ,&nbsp;Bing Xiu","doi":"10.1016/j.seminoncol.2025.152388","DOIUrl":"10.1016/j.seminoncol.2025.152388","url":null,"abstract":"<div><div>Lymphoma-associated hemophagocytic lymphohistiocytosis/syndrome (LA-HLH/LAHS) represents the most prevalent form of malignancy-associated HLH and is associated with an exceptionally poor prognosis. Emerging evidence implicates germline mutations as potential contributors to hematologic abnormalities, suggesting a genetic predisposition in affected individuals.</div><div>We conducted whole-exome sequencing (WES) on a cohort of 12 LA-HLH patients, with detailed analysis of 3 representative cases exhibiting coexisting genetic disorders. These cases were comprehensively evaluated for their clinical management strategies and therapeutic outcomes.</div><div>Our study revealed that gene mutations were detected in 6 patients (6/12), including 2 had somatic mutations, 3 had germline mutations, and 1 had both somatic and germline mutations. Among the 4 patients harbored germline mutations, 3 were diagnosed with concurrent genetic disease. Most patients (11/12) responded to immunochemotherapy for a short time and then progressed or relapsed, even after autologous hematopoietic stem cell transplantation (ASCT). Interestingly, two patients received CAR-T-cell therapy and achieved extremely good responses. One patient received CD19 CAR-T-cell infusion and had a PFS of 26 months. The other patient received double CAR-T infusions and has remained in complete remission for more than 2 years (until now).</div><div>This study proposes that LA-HLH may constitute a novel genetic subtype of lymphoma. Systematic genetic sequencing should be prioritized to guide precision treatment approaches in selected cases, including immunotherapies such as CAR-T-cell therapy. These insights redefine our understanding of LA-HLH pathogenesis and clinical intervention strategies.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152388"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody treatments for digestive cancers: Past, present, and future","authors":"Ikrame Dadi ,&nbsp;Thibault Mazard ,&nbsp;Lena-Marie Schmitt ,&nbsp;Tommy Chastel ,&nbsp;Andrei Turtoi ,&nbsp;Marie-Alix Poul ,&nbsp;Sophie Pattingre","doi":"10.1016/j.seminoncol.2025.152369","DOIUrl":"10.1016/j.seminoncol.2025.152369","url":null,"abstract":"<div><div>Gastrointestinal (GI) malignancies accounted for more than one in four cancer cases (4.8 million cases) in 2020. Among these, around 37% were colorectal followed by gastric (21%) and liver cancers (18%). Notably, GI cancers are responsible for nearly one-third of cancer-related mortality (3.4 million deaths worldwide). For decades, treatment relied primarily on conventional cytotoxic chemotherapies, which target rapidly dividing malignant cells but also cause significant harm to healthy tissue. Recent biotechnological advances enhanced our understanding of cancer biology, leading to the identification of specific molecular alterations and the development of new drugs, known as \"targeted therapies.\" These therapies include two major categories: small molecule kinase inhibitors (SMKIs), which inhibit dysregulated intracellular kinases, and monoclonal antibodies (mAbs), able to interfere with extracellular ligands, membrane receptors, or membrane-bound proteins.</div><div>This review aims to summarize recent advancements in the treatment of GI cancers using mAbs. We provide an overview of clinically approved mAbs in GI cancers, detailing their targets, mechanisms of action, and limitations. We differentiate between mAbs that directly target cancer cells and those that act on the tumor microenvironment (TME). Additionally, we discuss developments and technological optimizations used to improve the efficacy and specificity of these therapies.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152369"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA THUMPD3-AS1 promotes the proliferation and migration of esophageal cancer cells through the miR-29a-3p/ELK1/PRDX4 signaling pathway","authors":"Mingming Tang ,&nbsp;Jianjun Sun ,&nbsp;Zhigang Cai","doi":"10.1016/j.seminoncol.2025.152350","DOIUrl":"10.1016/j.seminoncol.2025.152350","url":null,"abstract":"<div><div>Esophageal cancer (ESCA) is a significant contributor to cancer-related deaths worldwide due to its aggressive nature and poor prognosis. Recent research indicates that non-coding RNAs are critical in tumor progression. This study intends to explore the interaction between LncRNA THUMPD3-AS1 and miR-29a-3p in ESCA advancement. By conducting bioinformatic analyses and validating differentially expressed genes in ESCA clinical samples, the regulatory relationship between THUMPD3-AS1, miR-29a-3p, ETS transcription factor (ELK1), and Peroxiredoxin 4 (PRDX4) was investigated using various functional assays. In vitro and in vivo experiments were also carried out to assess the impact of this interaction on tumor growth and ESCA progression. Results indicated elevated levels of THUMPD3-AS1 in ESCA tissues, acting as a sponge for miR-29a-3p, a microRNA known for its tumor-suppressive properties. This interaction relieved miR-29a-3p's inhibition of ELK1, resulting in increased PRDX4 expression. Functional tests confirmed that the THUMPD3-AS1/miR-29a-3p/ELK1/PRDX4 axis supports tumor proliferation, migration, and invasion in ESCA. Further validation of these findings was done through in vivo experiments. In conclusion, this study underscores the significance of the THUMPD3-AS1/miR-29a-3p/ELK1/PRDX4 axis as a crucial regulatory pathway in ESCA, unveiling its oncogenic role in enhancing tumor aggressiveness.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 4","pages":"Article 152350"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144579729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies","authors":"Chou-Yi Hsu ,&nbsp;Thikra Majid Muhammed ,&nbsp;Subasini Uthirapathy ,&nbsp;Irfan Ahmad ,&nbsp;Suhas Ballal ,&nbsp;Rishiv Kalia ,&nbsp;Premkumar J ,&nbsp;Subhashree Ray ,&nbsp;Riyadh Mohammed Mohsin ,&nbsp;Abid ALi A. Abiess","doi":"10.1016/j.seminoncol.2025.152370","DOIUrl":"10.1016/j.seminoncol.2025.152370","url":null,"abstract":"<div><div>Although studies have demonstrated that ovarian cancer cells can express immune checkpoint proteins like CTLA-4 and that higher levels of tumor-infiltrating lymphocytes are linked to better patient survival, clinical trials utilizing immune checkpoint inhibitors in ovarian cancer have not yielded encouraging results. Tumor heterogeneity and innate or acquired resistance associated with the tumor microenvironment (TME) may account for the inadequate response to ICIs. Understanding tumor immunobiology, identifying biomarkers for patient selection, and formulating suitable treatment regimens remain challenging, yet these are the aspirations for the future use of immunotherapy in ovarian cancer. Induced T cells express CD80 and CD86, providing a positive costimulatory signal via CD28. CTLA-4 antagonizes CD28, diminishing T cell activation and modulating the immunological response. Conversely, the negative regulation of CTLA-4 using monoclonal antibodies (mAbs), particularly ipilimumab, may stimulate T-cell responses against ovarian cancer antigens. We elucidate the mechanisms responsible for immunological suppression: T cell exhaustion and senescence in ovarian cancer. We also provide a synopsis of using CTLA-4 monoclonal antibodies in ovarian cancer alone or conjunction with other modalities (eg, chemotherapy). We finally delineate the challenges associated with responding to immunotherapy in ovarian cancer.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 4","pages":"Article 152370"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment","authors":"Mohd Suhail ,&nbsp;Shams Tabrez ,&nbsp;Mohammad Tarique ,&nbsp;Naoshad Muhammad ,&nbsp;Mohd Rehan ,&nbsp;Torki A. Zughaibi ,&nbsp;Mohammad Hassan Alhashmi","doi":"10.1016/j.seminoncol.2025.152353","DOIUrl":"10.1016/j.seminoncol.2025.152353","url":null,"abstract":"<div><div>Pancreatic cancer is one of the most lethal malignancies of the digestive tract, with a poor prognosis and a 5-year survival rate of less than 10%. The highly aggressive nature of pancreatic cancer results in a mortality rate of approximately 50% within the 6-month period of diagnosis. The absence of disease-specific symptoms significantly impedes early detection and timely intervention, contributing to its high mortality rate. Current treatment options such as radiotherapy, chemotherapy, and surgery are often inadequate for complete disease eradication and are associated with severe side effects that compromise patients' overall health. As a result, there is an urgent need for novel therapeutic strategies to address the rapidly increasing incidence of pancreatic cancer while ensuring safer, cost and more effective treatment alternatives. Plant-derived polyphenols have emerged as promising candidates due to their potent anticancer properties and minimal side effects compared to conventional therapies. In this review, we explore the biological significance and anticancer mechanisms of key polyphenols, including quercetin, resveratrol, apigenin, luteolin, EGCG, and curcumin, with a particular focus on their role in combating pancreatic cancer. Additionally, we provide a comprehensive summary of various pancreatic cancer studies, including ongoing clinical trials from the past decade.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 4","pages":"Article 152353"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood CD4+CD25+ T lymphocytes and TGF-β predict the prognosis in relapsed/refractory multiple myeloma treated with daratumumab","authors":"Hanyue Xue ,&nbsp;Fang Wei ,&nbsp;Ruiyang Li","doi":"10.1016/j.seminoncol.2025.152373","DOIUrl":"10.1016/j.seminoncol.2025.152373","url":null,"abstract":"<div><div>For patients with relapsed/refractory multiple myeloma (R/RMM), it is indispensable to choose a combination regimen based on Daratumumab, a kind of CD38-targeting monoclonal antibody (mAb), which has prominent therapeutic advantages. However, a few patients still experienced rapid progression, and the predictors of prognosis are little known. Thus, we analyzed peripheral blood (PB) CD4⁺CD25⁺ T lymphocytes and transforming growth factor-β (TGF-β) of R/RMM patients before Daratumumab treatment, to clarify their correlation with survival. Flow cytometry (FCM) was employed to detect, analyze, and compare CD4⁺CD25⁺T lymphocytes. Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify serum TGF-β. Clinical indicators were gathered and classified into quartiles. In R/RMM patients’ PB, we compared these markers between the upper and lower three quartiles. We found that CD4⁺CD25⁺ T lymphocytes (pcs/µL) and TGF-β in the PB of the R/RMM patients were higher than those of the newly diagnosed MM (NDMM) patients. Additionally, serum TGF-β of R/RMM patients was positively correlated to serum creatinine (Scr) (<em>P</em> &lt; 0.05). Finally, high CD4⁺CD25⁺ T lymphocytes (pcs/µL, 95% confidence interval [CI], 4.312–7.028, <em>P</em> = 0.001), CD4⁺CD25⁺ T lymphocytes (%, median PFS: 5.67 months, <em>P</em> = 0.043), and Scr (µmol/l, 95% CI, 5.378–7.422, <em>P</em> = 0.005) of R/RMM patients were significantly associated with inferior progression-free survival (PFS). These results suggest that patients with R/RMM are rich in CD4⁺CD25⁺ T lymphocytes and TGF-β. Additionally, R/RMM patients with elevated CD4⁺CD25⁺ T lymphocytes, TGF-β, and Scr before the treatment of daratumumab are more likely to have a poor prognosis.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 4","pages":"Article 152373"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144480909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 3-miRNA signature for noninvasive breast cancer detection","authors":"Amir Ebrahimi ,&nbsp;Davood Ghavi ,&nbsp;Zohreh Mirzaei ,&nbsp;Tahereh Barati ,&nbsp;Mahmood Shekari-Khaniani ,&nbsp;Hossein Gahramani-almangadim ,&nbsp;Sima Mansoori-Derakhshan","doi":"10.1016/j.seminoncol.2025.152363","DOIUrl":"10.1016/j.seminoncol.2025.152363","url":null,"abstract":"<div><div>As a key component of epigenetics, microRNAs (miRNAs) have provided promising insights into several aspects of Breast Cancer (BC). We have analyzed 2 BC tissue microarray datasets (GSE26659 and GSE40525), as well as 2 serum datasets (GSE106817 and GSE113486). The results were then intersected to identify commonly dysregulated miRNAs in the tissue and serum of BC patients. RNA-seq analysis was then applied to The Cancer Genome Atlas (TCGA) data. Briefly, 79 dysregulated miRNAs were identified in the tissue and serum of patients with BC of which 3 significantly dysregulated and previously unstudied miRNAs, let-7e-5p, miR-151a-5p and miR-887-3p, were chosen for quantification in the serum of cancer patients by RT-PCR followed by evaluation of their diagnostic and prognostic features. RT-PCR analysis revealed overexpression of let-7e-5p (logFC = 2.01, <em>P</em> &lt; .05) and miR-151a-5p (logFC = 1.48, <em>P</em> &lt; .05) whereas miR-887-3p was downregulated (logFC = 0.62, <em>P</em> &lt; .05) similar to microarray and RNA-seq data analysis. Based on regression analysis, a 3 miRNA-signature biomarker was proposed which had better diagnostic ability (AUC = 84.17%) compared to the ability of these miRNAs when assessed individually. Moreover, enrichment analysis revealed these miRNAs mediate vital cellular processes and biological functions that influence the development of cancer. Similarly, significant prognostic clinical characteristics were observed for these miRNAs. Overall, we have identified and validated a novel and proficient signature biomarker in serum of BC patients consisting of 3 miRNAs.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 4","pages":"Article 152363"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}